Table 1: Penetrance and location of pathological confirmed metastatic lesion(s).
# animals in Group
# animals that displayed metastasis in MRI and confirmed by Pathology
Pathology confirmation of MRI (primary imaging site)
Other confirmed Location (s)
|Mouse ID: MRI with pathology confirmation of metastasis|
(5 mice were EU due to xenograft size prior to observation of metastases)
1409, 1410, 1418, 1423
Lung, Kidney, Nodes, Peritoneal Wall
1405, 1407, 1408, 1411, 1413,1415, 1416, 1419, 1420, 1422
Percent penetrance with respect to the average time-to-metastasis for non-resected (plot A: time from implant) and resected (plot B: time from tumor resection) cohorts.
Frederick National Laboratory for Cancer Research – Special Thanks to Joseph D. Kalen, PhD, Lilia V. Ileva, MS, Lisa A Riffle, Nimit Patel, Keita Saito, PhD, Yvonne Evrard, PhD, Elijah Edmondson, DVM, PhD, Jessica Phillips, Simone Difilippantonio, PhD, Chelsea Sanders, Amy JanesJames, Lia Thang, Ulrike Wagner, Yanling Liu, PhD, John B. Freymann, and Justin Kirby.
Division of Cancer Therapeutics and Diagnosis/National Cancer Institute - James L. Tatum, MD, Paula M Jacobs, PhD, Melinda G. Hollingshead, DVM, and James H. Doroshow, MD
PixelMed Publishing – Special Thanks to David A. Clunie, MD
University of Arkansas for Medical Sciences – Special Thanks to Kirk E. Smith
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261201500003I. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.